Sanofi Plunges 5.96% on Mixed Phase III Trial Results

On May 30, 2025, Sanofi's stock experienced a significant drop of 5.96% in pre-market trading, reflecting investor concerns and market reactions to recent developments.

Sanofi, in collaboration with Regeneron, announced mixed results from their Phase III trials for the IL-33 antagonist itepekimab. The AERIFY-1 trial met its primary endpoint, showing a 27% reduction in the annual rate of moderate or severe exacerbations in COPD patients who were former smokers and had poor disease control. However, the AERIFY-2 trial did not achieve the same primary endpoint, despite early indications of benefit.

JPMorgan maintained its 'Neutral' rating for Sanofi, setting a price target of 110 euros. This decision comes amidst the mixed trial results, which have led to a cautious outlook from the investment bank.